Preprint Article Version 1 This version is not peer-reviewed

High LETM1 Expression Associates with Impaired Mitophagy and Bad Prognosis in Diffuse Large B-cell Lymphomas and Acute Myeloid Leukemias

Version 1 : Received: 27 July 2024 / Approved: 29 July 2024 / Online: 29 July 2024 (10:54:17 CEST)

How to cite: Salwa, A.; Ferraresi, A.; Vallino, L.; Maheshwari, C.; Moia, R.; Gaidano, G.; Isidoro, C. High LETM1 Expression Associates with Impaired Mitophagy and Bad Prognosis in Diffuse Large B-cell Lymphomas and Acute Myeloid Leukemias. Preprints 2024, 2024072292. https://doi.org/10.20944/preprints202407.2292.v1 Salwa, A.; Ferraresi, A.; Vallino, L.; Maheshwari, C.; Moia, R.; Gaidano, G.; Isidoro, C. High LETM1 Expression Associates with Impaired Mitophagy and Bad Prognosis in Diffuse Large B-cell Lymphomas and Acute Myeloid Leukemias. Preprints 2024, 2024072292. https://doi.org/10.20944/preprints202407.2292.v1

Abstract

Leucine zipper-EF-hand containing transmembrane protein 1 (LETM1) is a mitochondrial inner membrane protein involved in mitochondrial morphology and homeostasis. LETM1 is highly expressed in many human solid cancers and correlates with poor prognosis possibly due to mitochondrial dysfunction. However, the functional role of LETM1 in the progression of hematological malignancies remains to be elucidated. In this study, we found that higher LETM1 expression was associated with a short overall survival in Diffuse Large B-Cell Lymphoma (DLBCL) and in Acute Myeloid Leukemias (AML) patients. The transcriptomic analysis showed that LETM1 expression is positively correlated with oncogenic pathways (e.g., glucose transport, stem cell maintenance, mTOR and Wnt signaling pathways, mitotic G2/M phase transition, and cell proliferation) and negatively correlated with autophagy-related processes and apoptosis. In contrast, low expression of LETM1 associated with upregulation of BECLIN-1-dependent mitophagy, which in turn improves the prognosis in both DLBCL and AML patients. Our data suggest that LETM1 is a valuable prognostic marker and a possible therapeutic target for improving the clinical outcome in hematological malignancies.

Keywords

personalized medicine; lymphoma; leukemia; autophagy; mitochondria; overall survival; TCGA; bioinformatics.

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.